Close Menu

Helomics

Skyline will use Helomics' D-Chip bioinformatics repository of more than 149,000 tumors to develop cancer diagnostics.

The companies have partnered to jointly offer products and services for cancer specimen research and clinical data analysis.

As part of the deal, Helomics will promote MDNA's Prostate Core Mitomic Test and its liquid biopsy Prostate Mitomic Test in select US markets.

The firm will provide product enhancement and clinical lab services, including comprehensive tumor profiling using proprietary cell-based products and services.

The firms have eliminated several terms of their original deal and have cross-licensed IP to allow Med BioGene to license Gene FX Lung to other firms. 

The company also intends to eventually offer the two additions, which expand the granularity of its live-cell analysis platform, for clinical use.

Helomics will provide its technology to the GENE Consortium, formed to support the UK's 100,000 Genomes Project.

Helomics' tumor profiling products and services, including ChemoFx, will be available to more than 700,000 Prime Health Services providers.

Formerly called Precision Therapeutics, the company recently received a $60 million investment and ushered in new management.

NEW YORK (GenomeWeb) – Precision Therapeutics today announced a $60 million investment and a new name, Helomics.

Pages

The Washington Post reports that the CDC's SARS-CoV-2 test issues reflect earlier ones it had with Zika virus testing.

NPR writes that even with thousands of new COVID-19 papers, each should be evaluated based on its own quality.

Researchers traced a gene cluster linked to COVID-19 severity to Neanderthals, the New York Times reports.

In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.